Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | ADA | P00813 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652923 | 0.88 | ADORA2A (0.44) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5109141 | 0.83 | ADORA2A (0.42) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5654491 | 0.82 | ADORA2A (0.42) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5654270 | 0.80 | ADORA2A (0.47) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5096016 | 0.78 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL6010001 | 0.75 | ADORA2A (0.38) | ADORA2AADORA1 | |
| SCHEMBL5654222 | 0.74 | CHRM5 (0.36) | — | |
| SCHEMBL6010413 | 0.72 | ADORA2A (0.39) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5652423 | 0.72 | — | — | |
| SCHEMBL5102744 | 0.70 | ADORA2A (0.48) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | claimed |
| EP-1618109-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004092172-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.